Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab

Calvo, Pilar; Ferreras, Antonio; Adel, Fadwa Al; Wang, Yao; Brent, Michael H.

doi:10.1136/bjophthalmol-2014-305684

Cited by 38 publications

(32 citation statements)

References 14 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, GCs has been used in combination with anti-VEGF (Vakalis et al, 2015; Calvo et al; and 2015, Lim et al 2015) or photodynamic monotherapy (Selım et al, 2014). These combinations have been shown to have superior results than either treatment alone.…”

Section: Introductionmentioning

confidence: 99%

Glucocorticoid therapy and ocular hypertension

Dibas

Yorio

2016

European Journal of Pharmacology

View full text Add to dashboard Cite

The projected number of people who will develop age-related macular degeneration in estimated at 2020 is 196 million and is expected to reach 288 million in 2040. Also, the number of people with Diabetic retinopathy will grow from 126.6 million in 2010 to 191.0 million by 2030. In addition, it is estimated that there are 2.3 million people suffering from uveitis worldwide. Because of the anti-inflammatory properties of glucocorticoids (GCs), they are often used topically and/or intravitreally to treat ocular inflammation conditions or edema associated with macular degeneration and diabetic retinopathy. Unfortunately, ocular GC therapy can lead to severe side effects. Serious and sometimes irreversible eye damage can occur as a result of the development of GC-induced ocular hypertension causing secondary open-angle glaucoma. According to the world health organization, glaucoma is the second leading cause of blindness in the world and it is estimated that 80 million will suffer from glaucoma by 2020. In the current review, mechanisms of GC-induced damage in ocular tissue, GC-resistance, and enhancing GC therapy will be discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

Glucocorticoid therapy and ocular hypertension

Dibas

Yorio

2016

European Journal of Pharmacology

View full text Add to dashboard Cite

show abstract

“…An intravitreal dexamethasone implant (Ozurdex ® , Allergan, Irvine, California, USA) in combination with an anti‐VEGF preparation has been tested in small populations with promising results, but further studies will be needed (Calvo et al. ; Vakalis et al. ).…”

Section: Discussionmentioning

confidence: 99%

Anti‐vascular endothelial growth factors treatment of wet age‐related macular degeneration: from neurophysiology to cost‐effectiveness

Vottonen

2018

Acta Ophthalmologica

View full text Add to dashboard Cite

“…[66] The results of the study suggest the effectiveness of the dexamethasone-based implant in stabilizing vision, thus encouraging further investigation of the use of Oxurdex as a possible treatment for AMD. [66] Despite the advantage of requiring only one procedure to be implanted, biodegradable implants (like non-degradable implants) can still move from the original site of injection/implantation in the intraocular environment. Also, if not designed properly, a sudden increase of drug release may occur.…”

Section: Routes Of Ocular Administrationmentioning

confidence: 98%

Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation

Ratay

Bellotti

Gottardi³

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Dry eye disease (DED), age-related macular degeneration (AMD), and Uveitis are ocular diseases that significantly affect the quality of life of millions of people each year. In these diseases, the action of chemokines, pro-inflammatory cytokines, and immune cells drives a local inflammatory response that results in ocular tissue damage. Multiple therapeutic strategies have been developed to either address the symptoms or abate the underlying cause of these diseases. Herein, we will review the challenges to deliver drugs to the relevant location in the eye for each of these diseases as well as current and innovative therapeutic approaches that attempt to restore homeostasis within the ocular microenvironment.

show abstract

Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab

Abstract: DXI appears to be effective in vision stabilisation, decreasing IRF/SRF and improvement of CRT in eyes with refractory wet AMD.

Cited by 38 publications

References 14 publications

Glucocorticoid therapy and ocular hypertension

Glucocorticoid therapy and ocular hypertension

Anti‐vascular endothelial growth factors treatment of wet age‐related macular degeneration: from neurophysiology to cost‐effectiveness

Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation

Contact Info

Product

Resources

About